Myocarditis after BNT162b2 and mRNA-1273 vaccination

KF Larson, E Ammirati, ED Adler, LT Cooper Jr… - Circulation, 2021 - Am Heart Assoc
(COVID-19) vaccines have gained widespread use across the globe to prevent further spread
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Early studies …

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

…, AJ Clayburn, MR Spiegel, SE Baker, KF Larson… - Mayo Clinic …, 2020 - Elsevier
Objective To provide an update on key safety metrics after transfusion of convalescent plasma
in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated …

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

…, ER Lesser, SE Baker, KF Larson… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Convalescent plasma is the only antibody-based therapy currently available
for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence …

Convalescent plasma antibody levels and the risk of death from Covid-19

…, ER Whelan, AJ Clayburn, KF Larson… - … England Journal of …, 2021 - Mass Medical Soc
Background Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19)
under the presumption that such plasma contains potentially therapeutic …

Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study

…, AJ Clayburn, MK Grabowski, KF Larson… - PLoS …, 2021 - journals.plos.org
Background The United States (US) Expanded Access Program (EAP) to coronavirus disease
2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of …

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

…, ER Whelan, AJ Clayburn, KF Larson… - Nature …, 2021 - nature.com
Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have
harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…

[HTML][HTML] Rates among hospitalized patients with COVID-19 treated with Convalescent plasma: A systematic review and meta-analysis

…, AM Klompas, KL Kunze, KF Larson… - … : Innovations, Quality & …, 2023 - Elsevier
Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19. …

Convalescent plasma for infectious diseases: historical framework and use in COVID-19

…, CC Wiggins, SA Klassen, SE Baker, KF Larson… - Clinical Microbiology …, 2021 - Elsevier
Convalescent plasma has emerged as a promising therapeutic agent for patients with
coronavirus disease 2019 (COVID-19), has received emergency use authorization, and is being …

Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

…, V Herasevich, ER Whelan, AJ Clayburn, KF Larson… - medRxiv, 2021 - medrxiv.org
Background The United States (US) Expanded Access Program (EAP) to COVID-19
convalescent plasma was initiated in response to the rapid spread of severe acute respiratory …

Multiscale stellar associations across the star formation hierarchy in PHANGS–HST nearby galaxies: methodology and properties

KL Larson, JC Lee, DA Thilker… - Monthly Notices of …, 2023 - academic.oup.com
We develop a method to identify and determine the physical properties of stellar associations
using Hubble Space Telescope (HST) NUV−U−B−V−I imaging of nearby galaxies from the …